Hereditary nonpolyposis colorectal cancer

LetsGetChecked Launches myGeneticScreen, a Genetic Testing Service Designed to Deliver Personalized, Actionable Insights into Predisposition for Inherited Cancers and Cardiovascular Diseases

Retrieved on: 
Wednesday, February 21, 2024

LetsGetChecked, a global healthcare solutions company, announced today the launch of myGeneticScreen, a genetic testing service designed to provide patients with valuable and actionable insights into their predisposition for certain hereditary conditions with end-to-end support, including personalized health reports and access to genetic counseling.

Key Points: 
  • LetsGetChecked, a global healthcare solutions company, announced today the launch of myGeneticScreen, a genetic testing service designed to provide patients with valuable and actionable insights into their predisposition for certain hereditary conditions with end-to-end support, including personalized health reports and access to genetic counseling.
  • This addition to LetGetChecked’s genetics portfolio strengthens the company’s commitment to empowering people with accessible health information and care to live longer, happier lives.
  • Using a saliva specimen, myGeneticScreen analyzes 11 genes associated with three conditions recommended by the Centers for Disease Control and Prevention (CDC) as actionable Tier 1 conditions.
  • Offering a best-in-class experience, the genetic testing service includes pre- and post- genetic counseling.

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Retrieved on: 
Wednesday, February 21, 2024

The study, sponsored by the National Cancer Institute, part of the National Institutes of Health, will include up to 186 participants when fully enrolled and is now open to the randomized controlled portion of the trial.

Key Points: 
  • The study, sponsored by the National Cancer Institute, part of the National Institutes of Health, will include up to 186 participants when fully enrolled and is now open to the randomized controlled portion of the trial.
  • Each of the three vaccines in Tri-Ad5 targets different proteins associated with precancer and cancer cells.
  • The vaccine combination is studying whether activation of dendritic cells and training the immune system to recognize those proteins will destroy the precancer cells before the cancer occurs.
  • Safety and efficacy of these investigational agents have not been established by any Health Authority, including the FDA.

Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting

Retrieved on: 
Tuesday, March 5, 2024

SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16. The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.

Key Points: 
  • SAN FRANCISCO, March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16.
  • The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.
  • "The ACMG Annual Clinical Genetics Meeting is an incredible opportunity for our researchers and collaborators to highlight ongoing scientific advancements to support genetics-informed patient care," said W. Michael Korn, M.D., chief medical officer at Invitae.
  • Invitae plans to present posters (P164 and P073) about Lynch syndrome and VUS in mismatch repair (MMR) genes and multiplex assays of variant effects (MAVEs).

With Colorectal Cancer Rates Rising, the American Cancer Society and Colorectal Cancer Alliance Join Forces to Increase Screening

Retrieved on: 
Thursday, February 29, 2024

ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.

Key Points: 
  • ATLANTA, Feb. 29, 2024 /PRNewswire/ -- The American Cancer Society (ACS) and the Colorectal Cancer Alliance (Alliance) are joining forces on Your Colon is 45 - an initiative aimed at promoting colorectal cancer screening for individuals aged 45 and above.
  • According to the American Cancer Society's Cancer Fact & Figures, 2024 report , colorectal cancer is now the leading cause of cancer death in men and the second in women under 50 years old.
  • "By joining forces with the Colorectal Cancer Alliance, we can reach more individuals and empower them with vital information that can save lives."
  • Matching an American Cancer Society 2018 update to colorectal cancer screening guidelines , and the Alliance's call for earlier screening, the United States Preventive Services Task Force (USPSTF) released a recommendation statement lowering the age to begin colorectal cancer screening from age 50 to age 45 in 2021.

Colorectal cancer is the 2nd deadliest cancer in Canada, let's work together to avoid making it number one

Retrieved on: 
Monday, February 26, 2024

Colorectal cancer, affecting the colon and rectum, ranks as Canada's second deadliest cancer, claiming nearly 10,000 lives annually.

Key Points: 
  • Colorectal cancer, affecting the colon and rectum, ranks as Canada's second deadliest cancer, claiming nearly 10,000 lives annually.
  • Despite being preventable and highly treatable when detected early, the reluctance to participate in colorectal cancer screening has hindered early detection efforts.
  • This alarming reality serves as a stark reminder that vigilance and advocacy are paramount in the fight against colorectal cancer.
  • Join Colorectal Cancer Canada in our mission to save lives, break barriers, and promote equitable access to colorectal cancer resources across Canada.

EQS-News: Andera Partners co-leads a €67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom

Retrieved on: 
Tuesday, December 26, 2023

Paris, France – November 14, 2023 – Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens.

Key Points: 
  • Paris, France – November 14, 2023 – Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens.
  • Alongside Andera, Bpifrance (through its InnoBio 2 fund) and M Ventures co-led the round, with participation from Revelation Partners, Indaco Venture Partners, Panakès Partners, X-Gen Ventures, and other undisclosed investors together with continued support from existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures.
  • Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.
  • We look forward to supporting the company towards the further clinical validation of its platform.”

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round

Retrieved on: 
Tuesday, November 14, 2023

BASEL, Switzerland – 14th November 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors.

Key Points: 
  • BASEL, Switzerland – 14th November 2023 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned international healthcare investors.
  • Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.
  • Dr. Marina Udier, Chief Executive Officer of Nouscom, said: “This oversubscribed financing, in what is a challenging environment for all biotech companies, is testament to the faith that new and existing investors place in Nouscom and our best-in-class technology.
  • We are excited to support the company to continue bringing these innovative candidates closer to patients.”

Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Retrieved on: 
Friday, December 15, 2023

It was determined that the trial was unlikely to meet its primary endpoints upon completion.

Key Points: 
  • It was determined that the trial was unlikely to meet its primary endpoints upon completion.
  • The safety profile was consistent with previously reported studies of the fixed-dose combination of nivolumab and relatlimab.
  • Investigation of the fixed-dose combination of nivolumab and relatlimab as a treatment for other tumor types will continue as planned.
  • “Metastatic colorectal cancer is a challenging cancer to treat with high unmet needs.

Claris GenomiX Looks to Transform Precision Oncology Through Its Groundbreaking mRNA-Based Diagnostics

Retrieved on: 
Tuesday, December 12, 2023

"At Claris GenomiX, we have made significant discoveries and major advances in computational cancer biology and methods for developing clinical-grade diagnostics," said Dr. Steven Buechler, co-founder and CSO.

Key Points: 
  • "At Claris GenomiX, we have made significant discoveries and major advances in computational cancer biology and methods for developing clinical-grade diagnostics," said Dr. Steven Buechler, co-founder and CSO.
  • Precision oncology aspires to match a cancer patient with the drug or drugs that best treats the patient's particular tumor biology.
  • Quantification of mRNA using today's technology has the potential to take precision oncology to the next level.
  • Visit Claris GenomiX's website to learn more about ClarisInsight and to download a white paper on their precision oncology platform.

Volition Presents at the 5th Annual Congress of the International Liquid Biopsy Society

Retrieved on: 
Friday, November 17, 2023

HENDERSON, Nev, Nov. 17, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting at the 5th Annual Congress of Liquid Biopsy being held in Madrid, Spain.

Key Points: 
  • HENDERSON, Nev, Nov. 17, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting at the 5th Annual Congress of Liquid Biopsy being held in Madrid, Spain.
  • This data has generated significant interest from large diagnostic and liquid biopsy companies alike.
  • We are delighted to be presenting at the International Liquid Biopsy Society's Congress and furthering these discussions."
  • Volition has developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood.